WORLDWIDE INNOVATIVE NETWORKING IN PERSONALIZED CANCER MEDICINE
9-10 juillet 2009
Palais des Congrès de Paris, Porte Maillot
No doubt, one of the major future challenges in oncology will
be early diagnosis and individualized, tailored treatment of
cancer patients. Tailored cancer care is integrated into
the concept of cancer medicine with the aim to gain information about a patients gene and/or protein expression profile, or functional imaging modifications, in order to identify patients at risk. Yet, questions remain how and when this concept will be turned into clinical routine to change clinical management. We will address these questions to key speakers at the WIN symposium and to an audience encompassing physicians, scientists, cancer researchers, healthcare organizations, and patient advocates. We will also ask biotechnology providers and representatives of
the pharmaceutical industry.
Join us in Paris for the first open interactive WIN symposium. It will be exclusively dedicated to personalized cancer care, aiming at improved survival of cancer patients and thus a better life.
Register now, and actively participate in the WIN symposium by directing your questions to the symposium speakers. Once registered, a password and detailed instructions on how to participate in the forum will be delivered to each attendee.
ASCO ENDORSEMENT
As a nonprofit organization, ASCO is dedicated to achieving its charitable mission outlined by the organizations founders in 1964. ASCO strongly supports all types of cancer research, but in particular, patient-oriented clinical research. Endorsement implies that ASCO has approved in an official capacity the educational program, and has participated in its development. This program has the American Society of Clinical Oncologys approval for quality of educational content.
DISCLAIMER
ASCO endorsement does not constitute medical advice.
Health care providers should exercise their own independent medical judgment.
Organizing committee:
Gilles Vassal, Vladimir Lazar, Karen Fields, Isabelle Pelletier-Bressac, Hilario Matta, Jean Feunteun, Antoine Crouan, Michael Bia, Fabrice André
Scientific committee:
Chairman: Thomas Tursz, Institut Gustave Roussy, Villejuif, France,
Members:
- Ignacio I. Wistuba, MD Anderson Cancer Center, Houston, USA
- Manfred Schmitt, Technische Universitaet Muenchen, Munich, Germany
- George Simon, Fox Chase Cancer Center, Philadephia, USA
- René Bernards, Netherlands Cancer Institute, Amsterdam, The Netherlands
- Guo-Liang Jiang, Shanghai Cancer Center, Fudan University, China
- Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France
- Joost van den Oord, Katholieke Universiteit Leuven, University Hospitals, Leuven, Belgium
|
|
Worldwide Innovative Networking in personalized cancer medicine
8 Rue Tronchet
75008 PARIS
France
Téléphone: +33 (0)1 40 07 11 21
Fax: +33 (0)1 40 07 10 94
mbia@mfcongres.com
|
